STIs and sperm donation: screening, testing, and genetic risks explained simply

The building blocks of a credible screening programme

In practice, several layers fit together. Applying them consistently lowers the residual risk. The difference between a sperm bank and private donation is often how reliably the process is followed, rather than the individual test.

• Medical history and risk questions, including symptoms, new partners, travel, and relevant background.
• Blood tests for key viral infections and syphilis.
• Testing for bacterial STIs, especially chlamydia and often gonorrhoea.
• Depending on the programme, quarantine with repeat testing, or a defined test protocol, to detect infections that could not be identified at the initial examination.
• Clear documentation and traceability of dates, samples, and results.

When comparing options, ask for the release logic: how do they avoid missing a very recent infection?

Which infections are at the centre of donor screening?

Screening focuses on infections that can be serious and often begin without symptoms. Its exact scope depends on the country, programme and personal history. Common baseline investigations and risk-related additions should be considered together.

Common baseline investigations in clinical programmes

• HIV 1 and 2
• Hepatitis B
• Hepatitis C
• Syphilis
• Chlamydia, typically via molecular testing from urine or a swab

Add-ons depending on risk or recipient needs

• Gonorrhoea, often via molecular testing
• CMV, especially relevant in pregnancy contexts
• HTLV, in some regions or risk profiles
• Additional targeted checks after symptoms or travel exposures

The ECDC report on testing non-partner sperm donors describes these investigations in the European clinical setting. A clinician should help determine which tests are needed for a private donation. A test list by itself is not medical clearance.

Timing, NAT, antibodies and window periods

A negative result is sometimes mistaken for an absolute answer. A test is always a snapshot: was it taken at a time when that method could reliably detect the infection?

• Nucleic acid testing, or NAT, looks for genetic material from pathogens and can often identify infection earlier than antibody-only testing.
• Serological tests measure antibodies or antigens and are still central for particular pathogens.
• Testing soon after a risk exposure may feel reassuring while still being unable to exclude a recent infection reliably.

Repeat testing and clear rules between the test and release are therefore crucial. Without the right timing, the paperwork may show tests while leaving a practical gap.

For private donation, results need to be read alongside behaviour since the sample was collected. Agreed rules and documented repeat tests matter more than a very long panel.

Quarantine and release: why a second layer matters

For non-partner donation, material is commonly frozen before being released later. Further testing aims to identify infections that were not detectable when the donation was made, before the sample is used.

The ECDC’s 2018 report describes clinical protocols involving 180 days of quarantine and repeat testing, as well as approaches with additional NAT for HIV and hepatitis B and C. These are defined laboratory and release procedures. Ask the treating service which requirements apply to its programme. ECDC: quarantine, NAT and test timing

A self-chosen waiting period or a single private NAT does not automatically recreate a clinical release process. Fresh private semen in particular differs from screened and released sperm-bank material; these differences need to be discussed openly.

Making sense of results and abbreviations

Laboratory abbreviations can be bewildering. You do not need to study medicine, but you should know whether the report answers your question.

HIV

• A combination test measures antigen and antibodies and is commonly used to start screening.
• Some programmes add NAT to help detect a very early infection sooner.

Our article on the rapid HIV test helps explain what self-tests can and cannot establish.

Hepatitis B and C

Hepatitis testing often involves several results. The combination intended to exclude an acute or chronic infection matters more than one value. If it is unclear, request a written interpretation rather than accepting a simple yes or no.

Syphilis

Serological testing is usually used to investigate syphilis. Different laboratories use different terms. The assessment should not be reduced to a single method: what matters is a clear, documented conclusion.

Chlamydia and gonorrhoea

These bacterial STIs are often tested with NAT on urine or a swab. Collection technique, the method’s window period and new risks since testing all matter. A test just before donation may still miss a new infection. Read more about chlamydia.

Sperm washing: what it can and cannot establish

You may encounter claims that washed or prepared sperm prevents infection. Preparation can be part of a specialist medical procedure, but cannot by itself prove that a sample is free of infection. Infection testing and a medically justified decision on use are still needed.

When assessing safety, treat sperm preparation as one step rather than a shortcut. This is particularly relevant in private arrangements without standardised procedures.

Genetic risks and the limits of screening

Inherited risks matter alongside STIs and other infections. Many programmes use carrier tests to identify common recessive conditions and support matching. Which genes are included varies by provider and country.

A genetic panel cannot guarantee a healthy child. It lowers certain risks, but cannot cover all variants or every rare combination.

What matching means in practice

• For many autosomal recessive conditions, carriers are healthy themselves. A child’s risk rises if both genetic parents carry a relevant variant for the same condition.
• Matching may identify shared carrier status. Other inheritance patterns, including X-linked conditions, require a different assessment.
• A known condition in the family often needs individual investigation rather than reliance on a standard panel.

Ask both what the donor was tested for and which recipient information is taken into account, including how findings are interpreted genetically. A normal screen still leaves some risk. ASRM: genetic screening and counselling for donation

Sperm banks and private donation: practical differences in risk

Clinical programmes link tests to set dates, release procedures and documentation. This reduces risks without guaranteeing complete safety. Private donation does not automatically offer those controls. Unclear windows, missing repeat tests or findings that cannot be compared may introduce extra uncertainty.

Further reading: Private sperm donation: which health evidence should you see beforehand? and Sperm donation in Germany: process, costs, legal framework and donor register.

Private donation: planning with a clinician

• Up-to-date laboratory tests for both people, rather than screenshots or spoken assurances alone.
• Clear rules between the tests and donation, including avoiding risk exposures.
• Dates and repeat tests agreed with a clinician; pause and seek reassessment if new risks or symptoms arise.
• A clean handover, single-use equipment, clear labelling and documented consent.

Risk traps to avoid

• Old tests treated as permanent permission to donate.
• Vague statements that everything is negative without the laboratory, date and method.
• No agreed response to symptoms or risk exposure.
• Confusing medical safety with relationship matters such as trust, loyalty or pressure.

Myths and facts about STIs in sperm donation

Myth: a negative test means there is no risk

Fact: results are snapshots. Their value depends on timing, method and what has happened since the sample was taken. Rules between testing and use, together with repeat tests, are important.

Myth: lots of tests are automatically better than a sound process

Fact: a long list without release criteria can be falsely reassuring. A core panel, appropriate timing, clear rules for pausing after exposure and traceable records are what matter.

Myth: rapid tests are sufficient evidence

Fact: rapid tests may provide orientation, but generally cannot replace documented laboratory testing or a plan for window periods. Decisions about donor semen depend on method, date and a reliable testing chain.

Myth: sperm washing removes the need for screening

Fact: preparation may be a medical step, but is not proof of freedom from infection. It replaces neither diagnostic testing nor a justified decision to use the sample.

Myth: trust is enough for private donation

Fact: trust supports communication, but cannot replace medical assessment. Agreed investigations, clear reports and pauses when new risks arise can reduce risk, but cannot remove it all.

Questions you should request in writing

Clear answers mean less reliance on assumptions, whether you choose a sperm bank or private donation. Ideally, receive the key information as documents rather than chat messages alone.

• Which tests were done, on which dates, and in which laboratory?
• Which methods were used, such as NAT or serology?
• Were there risk exposures or symptoms since testing, and what is the rule then?
• How are quarantine and release organised, and what repeat testing is required?
• Which genetic tests are included, and how does matching work?
• How are findings, identity records and documentation kept over the long term?

Clarifying these questions can reduce medical risk and potential conflict by keeping expectations separate from facts.

Conclusion

STIs and other infections in sperm donation are reduced most reliably through a robust process: appropriate tests, correct timing, clear rules between testing and donation, and a release strategy that can catch recent infections. Understanding that logic helps you compare options and ask for evidence.